Previous 10 | Next 10 |
VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperforming historical controls. VBI-1901 is showing its ability to have an impact on the tu...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferie...
Updated phase 2 data from VBI Vaccines' (NASDAQ:VBIV) cancer vaccine candidate VBI-1901 found 18-month overall survival of 25% in one arm and 40% in another in recurrent glioblastoma (GBM). In the first arm, VBI-1901 was adjuvanted with granulocyte macrophage colony-stimulating factor (GM-CSF...
- Median overall survival and 18-month overall survival data continue to show improvements over historical controls 1 - One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline - Next steps : Recurrent GBM...
The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) granted marketing authorization to VBI Vaccines' (NASDAQ:VBIV) PreHevbri to prevent infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. The company said it can be expected that hepatitis D ...
PreHevbri™ is the only approved 3-antigen hepatitis B vaccine for adults in the United Kingdom Approval follows the European Commission’s marketing authorisation, granted in April 2022 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company ...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that health economics and outcomes research (HEOR) comparing the cost-effectiveness of the Company’s 3-anti...
VBI Vaccines press release (NASDAQ:VBIV): Q1 GAAP EPS of -$0.08 in-line. Revenue of $0.13M (-56.7% Y/Y) beats by $0.04M. Phase 2 clinical data from VBI-2601, VBI’s HBV immunotherapeutic candidate, is expected by year-end 2022. For further details see: VBI Vaccines GAAP EPS of -$0...
- VBI’s 3-antigen adult HBV vaccine available in the U.S. as PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and now approved in the European Union (EU)/European Economic Area (EEA) as PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] - New data from VBI&...
News, Short Squeeze, Breakout and More Instantly...
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...